Suruvodutide (also referred to as BI 456906) is a dual agonist peptide targeting both the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor (GCGR). This co-agonist approach is of significant interest in metabolic research, as simultaneous activation of both receptors has demonstrated enhanced effects on body weight reduction, hepatic lipid metabolism, and glucose homeostasis in preclinical and early clinical studies.
As a GLP-1 receptor agonist, suruvodutide promotes insulin secretion and suppresses appetite, whilst the glucagon receptor component augments energy expenditure and promotes hepatic fat mobilisation. This dual mechanism makes it a compelling research tool in the study of obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), and non-alcoholic steatohepatitis (NASH).
Peptician supplies suruvodutide as a high-purity lyophilised powder with purity exceeding 98%, as confirmed by HPLC analysis. Each 10mg vial is intended for in vitro and in vivo research applications under controlled laboratory conditions.
Storage: Store at -20°C. Protect from light and moisture. Reconstituted solutions should be aliquoted and stored at -80°C.
Molecular Formula
C₁₄₉H₂₄₀N₄₂O₄₅
Molecular Weight
3313.8 g/mol
Purity
>98%
CAS Number
2413929-21-0
Form
Lyophilised Powder
Research Applications
Obesity and body weight regulation, Type 2 diabetes and glucose homeostasis, Non-alcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatotic liver disease (MASLD), Hepatic lipid metabolism, Energy expenditure and metabolic rate research
For research purposes only. Not for human use.
Reviews
There are no reviews yet.